Bioaffinity Technologies, INC

bioAffinity Technologies announces a nationwide federal healthcare distribution agreement with AvMEDICAL to market its CyPath Lung diagnostic test.

BioAffinity Technologies announced strong second quarter 2026 results, with CyPath Lung test volume surging 216% year-over-year and revenue increasing 19%, while advancing its diagnostic and therapeutic pipeline.

bioAffinity Technologies received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, potentially leading to delisting.

bioAffinity Technologies announced the publication of a clinical review and white paper by its Chief Medical Officer, detailing a framework for integrating CyPath Lung into pulmonary nodule evaluation and cancer surveillance.

bioAffinity Technologies and Pictor, Inc. are collaborating to develop and commercialize next-generation diagnostic tests for asthma and COPD, aiming to improve personalized treatment through advanced proteomic analysis.

bioAffinity Technologies announced over 200% year-over-year sales growth for its CyPath Lung diagnostic in Q2 2026, driven by increased physician adoption and repeat utilization.

bioAffinity Technologies reports increased revenue for its CyPath Lung diagnostic test but faces substantial doubt about its going concern status and a Nasdaq delisting warning.

BioAffinity Technologies reported a widened net loss of $5.1 million in Q3 2025, despite an 86% increase in CyPath Lung revenue, as it navigates strategic shifts and capital raises.

BioAffinity Technologies reports increased net losses and significant liquidity challenges, raising substantial doubt about its ability to continue as a going concern, despite growth in its CyPath Lung diagnostic test revenue and new patent grants.

bioAffinity Technologies' Q1 2025 revenue decreased by 23% due to strategic actions, but CyPath Lung testing revenue increased significantly.

bioAffinity Technologies saw a significant increase in revenue in Q3 2024, primarily due to the acquisition of a clinical pathology lab, but continues to operate at a loss and faces substantial doubt about its ability to continue as a going concern.

bioAffinity Technologies reports a net loss of $2.1 million for Q2 2024, with significant revenue growth driven by the acquisition of Precision Pathology Laboratory Services.

bioAffinity Technologies reported a 34% consolidated revenue decrease to $6.2 million in 2025, driven by strategic divestitures, while its CyPath Lung diagnostic revenue surged 87% and the company raised $16.9 million in equity.

bioAffinity Technologies files an amendment to its annual report on Form 10-K to include information required by Part III regarding directors, executive officers, and corporate governance.

bioAffinity Technologies' 10-K filing reveals a 270% revenue increase driven by the PPLS acquisition, alongside strategic cost-saving measures and continued focus on CyPath Lung commercial growth.

BioAffinity Technologies outlines the terms of its common stock and tradeable warrants, along with corporate governance and risk factors, in its annual 10-K filing.

Xavier Trinidad Reveles, COO of bioAffinity Technologies, reports acquisition and disposal of common stock on January 10, 2025.

Executive Chairman Steven Girgenti reports acquisition and disposal of bioAffinity Technologies stock, including a grant of restricted shares and shares held by a trust.

Maria Zannes, President & CEO of bioAffinity Technologies, reports the acquisition of 37,037 shares of restricted common stock.

James Michael Edwards, VP and CFO of bioAffinity Technologies, reports the acquisition of 6,172 shares of common stock through a grant and the resulting adjusted beneficial ownership.

Timothy P. Zannes, Secretary, EVP, and General Counsel of bioAffinity Technologies, acquired 8,641 shares of common stock through a grant, increasing his holdings to 54,765 shares.

James Michael Edwards, VP and CFO of bioAffinity Technologies, acquired 100,000 shares of common stock on November 5, 2024, through a grant of restricted shares.

BioAffinity Technologies, Inc. calls for its Annual Meeting to approve a reverse stock split, significant equity plan expansion, and authorization for future dilutive capital raises.

BioAffinity Technologies, Inc. issued a supplement to its proxy statement to correct a clerical error in the number of outstanding common shares for its upcoming Special Meeting.

bioAffinity Technologies calls a Special Meeting to approve significant share issuances, anti-dilution adjustments, and a large equity plan increase, signaling substantial future dilution.

bioAffinity Technologies, Inc. has filed a Definitive Proxy Statement (Schedule 14A) with the U.S. Securities and Exchange Commission.

bioAffinity Technologies, a developer of noninvasive lung cancer diagnostics, is calling an Annual Meeting on July 25, 2025, to seek shareholder approval for a reverse stock split, a substantial increase in authorized shares, and the issuance of millions of shares from warrant exercises, primarily to address Nasdaq listing compliance and facilitate future capital raising.

bioAffinity Technologies is holding a special meeting to seek stockholder approval for the issuance of shares related to warrants from a recent offering.

BioAffinity Technologies, Inc. has filed details regarding its Pre-funded Common Stock Purchase Warrant, outlining terms for exercise, pricing, and potential adjustments.

bioAffinity Technologies, Inc. has filed a registration statement for a public offering of common stock and pre-funded warrants to raise approximately $4 million for working capital.

bioAffinity Technologies has filed a registration statement for the resale of up to 497,483 shares of common stock issuable upon the exercise of warrants and conversion of Series B preferred stock.

bioAffinity Technologies, Inc. is offering up to 729,927 shares of common stock and pre-funded warrants in a best efforts public offering to raise approximately $3.4 million, while facing Nasdaq delisting threats.

BioAffinity Technologies, Inc. announced a public offering of common stock and warrants to raise capital, following a reverse stock split and ongoing Nasdaq compliance challenges.

bioAffinity Technologies, Inc. filed an S-1/A registration statement for the resale of up to 32,495,628 shares of common stock by selling stockholders, while facing imminent delisting from Nasdaq and a going concern warning.

A group of investment entities led by Michael Bigger reported a complete divestment of their beneficial ownership in bioAffinity Technologies, Inc. common stock, falling below the 5% threshold.

Richard K. Crumly, along with ADAMAS LLC and BMUS PARTNERS LLC, has filed a Schedule 13G disclosing a collective beneficial ownership of 11.2% of bioAffinity Technologies, Inc.'s common stock.